NCT07354568Recruiting
Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock
Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock: a French Multicenter Cohort
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
Mixed cardiogenic-vasoplegic shock (M-CS) represents a distinct and severe phenotype of cardiogenic shock characterized by concomitant myocardial dysfunction and inappropriate systemic vasodilation. Despite its clinical relevance, the epidemiology, management, and outcomes of M-CS remain poorly defined. This retrospective, multicenter, observational registry aims to evaluate the clinical outcomes and prognostic factors associated with mixed cardiogenic-vasoplegic shock. The study will analyze clinical, biological, and invasive hemodynamic data routinely collected during patient management for M-CS. All included patients will have been admitted for cardiogenic shock, with or without vasoplegia, defined by low cardiac output and, when present, decreased systemic vascular resistance despite adequate filling pressures requiring vasopressor support. The primary objective is to describe mortality and organ failure rates, while secondary analyses will identify determinants of adverse outcomes and potential phenotypic subgroups. The PROMIX registry will be conducted across three French university hospitals (CHU Amiens-Picardie, CHU Dijon-Bourgogne, and CHU Rouen-Normandie). This study is non-interventional, involving only data obtained as part of routine critical care, and will provide the first multicenter overview of this complex and underrecognized form of cardiogenic shock.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2500 (estimated)
- First submitted
- 15 Dec 2025
- Start date
- 20 Oct 2025
- Primary completion date
- 1 Jan 2027
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- Diseases
- Coronary artery disease
- NCT number
- NCT07354568
What you commit to
- Study type: Observational
- Planned participants: 2500
- From 20 Oct 2025 to the primary completion date, 1 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Fulminant hepatic failure,
Other
- Missing key data, particularly regarding vasopressor doses and outcomes.
- Pregnant women
- Non-eligible shock etiologies, including but not limited to:
- Anaphylactic shock,
- Isolated hemorrhagic shock,
- Severe burns or major trauma,
- Severe acute pancreatitis,
- Neurogenic shock.
- Adult under legal protection (guardianship, curatorship, or judicial protection).
Who the study is looking for
- Adult patient (\>18 years old)
- Admitted to an intensive care unit for cardiogenic shock, at least SCAI stage C
- No opposition to data use
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chu Amiens Picardie Coordinator of this site? Confirm its status | Amiens | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.